Preferred Label : Renal Cell Carcinoma Pathway;
NCIt related terms : Renal cell carcinoma;
Alternative definition : KEGG: Renal cell carcinoma (RCC) is a heterogeneous term comprising a group of neoplasms
of renal origin. There are 4 major histologic subtypes of RCC: conventional (clear
cell RCC, 75%), papillary (15%), chromophobic (5%), and collecting duct (2%). Multiple
genes are involved in the molecular pathogenesis of RCC. VHL is a tumor suppressor
gene responsible for hereditary (von Hippel-Lindau) and sporadic variants of conventional
(clear cell) RCC. In the absence of VHL, hypoxia-inducible factor alpha (HIF-alpha)
accumulates, leading to production of several growth factors, including vascular endothelial
growth factor and platelet-derived growth factor. An oncogene, MET has been found
to be mutant in cases of hereditary papillary renal cancer (HPRC), although the incidence
of c-MET mutations is low in sporadic papillary RCC. Once activated, MET mediates
a number of biological effects including motility, invasion of extracellular matrix,
cellular transformation, prevention of apoptosis and metastasis formation. Mutations
in the fumarate hydratase (FH) gene cause hereditary leiomyomatosis and renal cancer
syndrome (HLRCC) papillary renal tumors, although the incidence of FH mutations in
sporadic tumors is unknown. Loss of functional FH leads to accumulation of fumarate
in the cell, triggering inhibition of HPH and preventing targeted pVHL-mediated degradation
of HIF-alpha. BHD mutations cause the Birt-Hogg-Dube syndrome and its associated chromophobe,
hybrid oncocytic, and conventional (clear cell) RCC. The incidence of BHD mutations
in sporadic renal tumors is not known.;
KEGG ID : hsa05211;
Origin ID : C91501;
UMLS CUI : C2984311;
Automatic exact mappings (from CISMeF team)
Semantic type(s)
has_gene_product_element
pathway_has_gene_element